Skip to main content
SGMT
NASDAQ Life Sciences

Sagimet Q2 2026: $257.6M Cash and Phase 3 Acne Trial Set for 2H 2026

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$9.2
Mkt Cap
$585.534M
52W Low
$4.5
52W High
$10.062
52W Position info
104% above low
Off High info
8.6% below high
Rel. Volume info
1.6× avg
Market data snapshot near publication time

SGMT has more than doubled off its 52-week low of $4.5.

Summary

Sagimet Biosciences posted a Q2 2026 net loss of $14.0 million and held $257.6 million in cash, funding operations through 2028. Its lead acne candidate, denifanstat, is on schedule for a U.S. Phase 3 trial start in the second half of 2026, and an updated investor presentation highlights a sharpened focus on dermatology.


Key Events · Earnings and Guidance · SGMT

  • Q2 2026 Financial Results

    For the second quarter, the company reported a net loss of $14.0 million, with R&D expense of $11.5 million and G&A expense of $4.3 million. As of June 30, 2026, cash, cash equivalents, and marketable securities stood at $257.6 million.

  • Cash Runway Through 2028

    The $257.6 million cash position—which includes $175 million from an April 2026 equity raise—is expected to fund operations through 2028 and carry the company through the denifanstat Phase 3 data readout.

  • Denifanstat Phase 3 on Track

    Pending FDA agreement, the registrational Phase 3 trial of denifanstat in moderate to severe acne for the U.S. is expected to initiate in the second half of 2026.

  • TVB-3567 Advancing

    The first-in-human Phase 1 trial of the follow-on FASN inhibitor TVB-3567 is ongoing, and subject to regulatory feedback, a Phase 2 trial in acne is expected to begin before the end of 2026.


Analysis · SGMT · Life Sciences

A net loss of $14.0 million in Q2 2026 reflects Sagimet's investment in its dermatology pipeline, with R&D spending at $11.5 million. The company's $257.6 million cash balance extends its runway through 2028, comfortably covering the anticipated readout of the denifanstat Phase 3 trial in moderate to severe acne. An updated investor presentation underscores the strategic pivot to dermatology: the U.S. Phase 3 trial for denifanstat remains on track to begin in the second half of 2026, while the follow-on FASN inhibitor TVB-3567 is advancing toward a Phase 2 start before year-end. Bolstered by a $175 million equity raise in April 2026, the strong cash position removes near-term financing risk and enables execution on these key clinical milestones.

How filings like this one have moved

In the 30 days to Nov 4, 2026, 32.4% of the 2199 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, SGMT was trading at $9.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $585.5M. The 52-week trading range was $4.50 to $10.06. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

SGMT - Latest Insights

SGMT
Oct 01, 2026, 5:41 PM EDT
Source: Seeking Alpha
Importance Score:
8
Price at Filing: $9.24
Real-time Price: $9.85 info
Change: +$0.610 (+7%) info
Market Cap: $702.708M info
SGMT
Sep 30, 2026, 6:00 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $10.03
Real-time Price: $9.85 info
Change: -$0.180 (-2%) info
Market Cap: $702.708M info
SGMT
Sep 30, 2026, 5:53 PM EDT
Filing Type: 424B5
Importance Score:
7
Price at Filing: $10.03
Real-time Price: $9.85 info
Change: -$0.180 (-2%) info
Market Cap: $702.708M info
SGMT
Sep 30, 2026, 6:19 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $9.99
Real-time Price: $9.85 info
Change: -$0.140 (-1%) info
Market Cap: $702.708M info
SGMT
Sep 30, 2026, 6:09 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $9.43
Real-time Price: $9.85 info
Change: +$0.420 (+4%) info
Market Cap: $702.708M info